Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications

Lúcio Muniz Júnior, Roberto and Godói, Isabella Piassi and Reis, Edna Afonso and Garcia, Marina Morgado and Guerra Júnior, Augusto Afonso and Godman, Brian and Ruas, Cristina Mariano (2019) Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 19 (4). pp. 473-482. ISSN 1473-7167

Text (Muniz-Junior-etal-ERPOR-2018-Consumer-willingness-to-pay-for-a-hypothetical-Zika-vaccine) Muniz_Junior_etal_ERPOR_2018_Consumer_willingness_to_pay_for_a_hypothetical_Zika_vaccine.pdf Accepted Author Manuscript Restricted to Repository staff only until 4 December 2019. Download (778kB) | Request a copy from the Strathclyde author

Abstract

ABSTRACT : Background: Zika virus is a newly emerging infection, associated with increasingly large outbreaks especially in tropical countries such as Brazil. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. Information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help price setting discussions in the future in Brazil, starting with the private market. Methods: A cross-sectional study conducted among residents of Minas Gerais, Brazil, regarding their WTP for a hypothetical Zika Vaccine. The mean effective protection was 80%, with the possibility of some local and systemic side- effects. Results: 517 people were interviewed. However, 28 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), had completed high school (49.7%), were employed (71.2%), had private health insurance (52.7%), and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine (one dose) was US$31.34 (BRL100.00). Conclusion: Such discussions regarding WTP can contribute to decision-making about prices once a Zika vaccine becomes available in Brazil alongside other ongoing programs to control the virus.